Sort
4,870 grants matching “glp 1”
Novel Antibacterials Targeting Gram-negative Nonfermenters
$261,038Michelle M. Butler · Microbiotix, Inc · R43 · FY2010 · AI
REDUCIBLE POLYAMIDO ETHYLENIMINE FOR GLP-1 PLASMID DELIVERY
$260,741Sung Wan Kim · University Of Utah · R01 · FY2010 · DK
Enhancement of Beta Cell Function with Pharmacologic and Sleep Apnea Treatment
$260,687David A Ehrmann · University Of Chicago · U01 · FY2014 · DK
CEST MRI Agents for Receptor Imaging
$260,599Michael T McMahon · Johns Hopkins University · P41 · FY2019 · EB
CEST MRI Agents for Receptor Imaging
$260,599Michael T McMahon · Johns Hopkins University · P41 · FY2018 · EB
CEST MRI Agents for Receptor Imaging
$260,599Michael T McMahon · Johns Hopkins University · P41 · FY2020 · EB
Triagonist Peptide Therapeutics for Neuroprotection
$259,613Krishna Kumar · Velum, Inc. · R41 · FY2021 · GM
Novel Antibacterials Targeting Gram-negative Nonfermenters
$259,512Michelle M. Butler · Microbiotix, Inc · R43 · FY2009 · AI
Immune Responses to CMV DNA Vaccination
$258,937Vical, Inc. · R01 · FY2005 · AI
Potential Mechanisms of Glucagon-like peptide-1 in Fatty Liver Disease
$258,570Frank A. Anania · Emory University · R01 · FY2007 · DK
IMPARIED AMINO-ACID SENSING/SIGNALING IN BONE MARROW OSTEOPROGENITOR CELLS
$258,454Carlos Miguel Isales · Augusta University · P01 · FY2013 · AG
Project-004
$258,164Jane M Liebschutz · University Of Pittsburgh At Pittsburgh · UG1 · FY2025 · DA
REDUCIBLE POLYAMIDO ETHYLENIMINE FOR GLP-1 PLASMID DELIVERY
$258,135Sung Wan Kim · University Of Utah · R01 · FY2012 · DK
REDUCIBLE POLYAMIDO ETHYLENIMINE FOR GLP-1 PLASMID DELIVERY
$258,135Sung Wan Kim · University Of Utah · R01 · FY2011 · DK
Development of Anti-necrosis Drug for Acute Brain Injury
$257,000Junying Yuan · Harvard Medical School · U01 · FY2008 · NS
CEST MRI Agents for Receptor Imaging
$256,587Michael T McMahon · Johns Hopkins University · P41 · FY2021 · EB
Identification of Molecular Biomarkers in Rat Sperm and Testis Exposed to BPA
$256,270Kim Boekelheide · Brown University · U01 · FY2013 · ES
Preclinical Development of VERSAMAB-101 for Spinal Cord Injury
$256,122Miao Sun · Versapeutics Inc · R43 · FY2021 · NS
Theranostic system for targeted, sustained-delivery with quantitative "hot spot" MPI of magnetic extracellular vesicles
$255,902Dian Respati Arifin · Johns Hopkins University · R21 · FY2024 · EB
Development of microencapsulated PI301 targeting lung GABAergic signaling
$255,841Douglas C. Stafford · Pantherics Incorporated · R43 · FY2022 · HL
Identification of Molecular Biomarkers in Rat Sperm and Testis Exposed to BPA
$255,327Kim Boekelheide · Brown University · U01 · FY2012 · ES
Clinical Testing of an Insulin Analog
$254,997Michael Aaron Weiss · Thermalin Diabetes, Llc · R41 · FY2009 · DK
Effects of Intermittent Fasting on Glycemic Control in Patients with Diabetes
$254,508Felicia Steger · University Of Kansas Medical Center · P20 · FY2024 · GM
Enhancement of Beta Cell Function with Pharmacologic and Sleep Apnea Treatment
$254,321David A Ehrmann · University Of Chicago · U01 · FY2013 · DK
A Human Laboratory Study of Exenatide for Reducing the Reinforcing Effects of Cocaine
$254,265Christopher D Verrico · Baylor College Of Medicine · R21 · FY2023 · DA